(Source: Wave Life Sciences Ltd) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 11, 2015-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a preclinical biopharmaceutical company using its proprietary chemistry platform to design, develop and commercialize a broad pipeline of first-in-class or best-in-class stereopure nucleic acid therapeutics candidates, today announced the pricing of its initial public offering of 6,375,000...
↧